Shares of Wockhardt Ltd surged 5% to touch a day’s high of Rs 1,775 on 28th July, after the company stated a medical case where its novel antibiotic Zaynich was used to treat a critically ill US liver transplant patient suffering from a pan-drug resistant infection.

Wockhardt shared details of a successful case. Its antibiotic Zaynich treated a US liver transplant patient with an infection resistant to all available antibiotics. The case study, published in the Journal of Antimicrobial Chemotherapy – AMR and co-authored by clinicians from top US hospitals, highlighted Zaynich’s effectiveness against pan-drug-resistant pathogens.

The patient had two infections resistant to all recent antibiotics. Initial treatment with cefiderocol and eravacycline failed, as the infection persisted and worsened. Doctors then obtained emergency access to Zaynich, which was given for 14 days around the time of the transplant.

Within 11 days, the patient showed significant improvement. The patient was transferred out of the ICU, and follow-up scans revealed no active infection. Six weeks post-treatment, the patient remained infection-free. This made the transplant successful and allowed chemotherapy to resume.

At 1:31 PM, the shares of Wockhardt Ltd were trading 0.44% higher at Rs 1,684.80 on NSE.

Got Wockhardt-Related Questions? The Analyst is Ready.

Unlock profitable opportunities every day! Unicorn Signals provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Unicorn Signals and start winning now!